ISPIRE's 2023 Annual Report: Milestone Achieved with Revenue Growth

Business by 2FIRSTS.ai

Sep.19.2023

ISPIRE's 2023 Annual Report: Milestone Achieved with Revenue Growth

ISPIRE reports 31.2% revenue growth in 2023 fiscal year, reaching $115.6 million, driven by CBD and e-cigarette sales.

On September 19, ISPIRE (ISPR.US), a tech company known as "Fog Hemp Technology," released its fiscal year 2023 report. The performance report reveals that ISPIRE experienced a revenue growth of 31.2% in the 2023 fiscal year, reaching a total of $115.6 million.

Michael Wang, Co-CEO of ISPIRE, has described the 2023 fiscal year as a significant milestone for the company. Revenue from CBD and e-cigarette products saw impressive growth of 100.4% and 10.9% respectively, contributing to an overall revenue increase of 31.2%. This growth was primarily driven by a doubling of income from ISPIRE's CBD vaporizer products in the United States and increased sales of e-cigarette products in Europe.

He stated that the key to this success is ISPIRE's multi-pronged strategy: expanding the sales of CBD vaporizer products to provide innovative solutions for both medical and recreational sectors.

He also stated that ISPIRE's factory in California, United States, will launch its first fully automated assembly line by the end of 2023. Furthermore, ISPIRE is actively considering Southeast Asia as a potential manufacturing hub for future business, aiming to further optimize production capacity.

References:

[1] Ispire Technology Inc. Reports Financial Results for the Fiscal Full Year 2023

Also Read:

[1] ISPIRE reports 31.2% Revenue Growth in 2023

#Legislation #E-liquids #Asia #India #Ispire Technologies Inc.#Report

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Regulation Shift：Policy Updates and Market Impact

From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release

China-based Shenzhen Huabao Collaborative Innovation Technology Research Institute Co., Ltd. has filed a patent application for a nicotine-ascorbic acid cocrystal, exploring a new solid-state form of nicotine. The patent proposes applications across e-liquids, heated tobacco sticks, oral tobacco, chewing tobacco and snuff. In nicotine pouch tests disclosed in the filing, cocrystal formulations showed less than a 6% decline in nicotine content after three months of accelerated storage and a release profile combining early-stage release with sustained delivery over 60 minutes. The filing reflects exploration of nicotine forms beyond conventional nicotine base and nicotine salts.

Aug.13

China’s HTP Exports Fell 14.3% in H1 2026 as Russia and Belarus Accounted for 76% Lead

In H1 2026, China’s HS 24041100 exports stood at $1.32 million, down 14.3% YoY, with volume falling 17.2% to 55.33 tons. Market distribution shifted drastically amid overall export drops. Exports to Russia and Belarus totaled $1 million, taking 76.0% of all shipments versus 29.5% in H1 2025. Belarus became the top destination with export value jumping 177.5%, while the Philippines, Singapore and Indonesia’s combined share slumped from 49.3% to 11.2%.Domestically, Yunnan led exporter registrations; Jiangsu and Shanghai were key suppliers, yet Anhui and Sichuan had no exports. Heavy concentration means order or declaration changes for Russia/Belarus greatly affect national aggregate data. The data shows customs entry points (not end markets), covering tobacco consumables only, excluding heating equipment and the complete HTP supply chain.

Aug.11